Search Result
Results for "
virus neutralization
" in MedChemExpress (MCE) Product Catalog:
2
Biochemical Assay Reagents
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0215
-
-
-
- HY-P99756
-
|
MEDI8897
|
RSV
|
Infection
|
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
|
-
-
- HY-P990794
-
|
|
TNF Receptor
Dengue Virus
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) is a rat-derived IgG1 antibody inhibitor, targeting to TNF-alpha/TNFSF2. Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) neutralizes of TNF-alpha. Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) can be used for the researches of cancer, infection and immunology, such as dengue virus and B16K1 tumor .
|
-
-
- HY-P99750
-
|
CT-P23
|
Influenza Virus
|
Infection
|
|
Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A .
|
-
-
- HY-P990015
-
|
VIR-3434
|
HBV
|
Infection
|
|
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
-
- HY-164485
-
|
|
Toll-like Receptor (TLR)
SARS-CoV
|
Infection
|
|
INI-4001 is a TLR7/8 agonist and vaccine adjuvant. INI-4001 regulates innate and adaptive immune responses by activating murine TLR7 and human TLR7/TLR8. INI-4001 enhances IgG and neutralizing antibody responses against Powassan virus (POWV), reduces viral loads in the brain, liver and spleen, provides complete protection against lethal POWV challenge, and skews immune responses toward a Th1 phenotype. When INI-4001 is used in combination with Al (OH)3 and SARS-CoV-2 RBD antigen, it efficiently adsorbs to Al (OH)3, promotes Th1 immunity and enhances SARS-CoV-2 neutralizing antibody responses. INI-4001 is applicable to research related to Powassan virus infection and COVID-19 .
|
-
-
- HY-P991446
-
|
|
Influenza Virus
|
Infection
|
|
MEDI-8852 is a human IgG1 monoclonal antibody against influenza A virus hemagglutinin (HA). MEDI-8852 binds to the conserved HA stalk epitope and neutralizes viral infectivity. MEDI-8852 reduces viral titers in mouse lung tissues. MEDI-8852 is applicable to research related to pandemic influenza . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
-
- HY-P99342
-
|
REGN10987
|
SARS-CoV
|
Infection
|
|
Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .
|
-
-
- HY-153235
-
|
|
mRNA
SARS-CoV
Liposome
|
Infection
|
|
COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein. COVID-19 Spike Protein undertakes the functions of virus binding with host cell receptors, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design. COVID-19 Spike Protein mRNA-LNP can be used for RNA delivery, vaccine formulation and design targeting SARS-CoV-2 .
|
-
-
- HY-P990223
-
|
|
Interleukin Related
|
Infection
Others
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-15 Antibody (AIO.3) is a rat-derived IgG2a λ type antibody inhibitor, targeting to mouse IL-15. Anti-Mouse IL-15 Antibody (AIO.3) can neutralize IL-15. Anti-Mouse IL-15 Antibody (AIO.3) can be used for the researches of cancer, infection and inflammation, such as hepatitis virus infection and esophagitis .
|
-
-
- HY-B0215S
-
|
N-Acetylcysteine-d3; N-Acetyl-L-cysteine-d3; NAC-d3
|
Isotope-Labeled Compounds
Reactive Oxygen Species (ROS)
Endogenous Metabolite
Apoptosis
Ferroptosis
Influenza Virus
Disulfidptosis
|
Infection
Neurological Disease
|
|
Acetylcysteine-d3 is the deuterium labeled Acetylcysteine. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases. Acetylcysteine induces cell apoptosis. Acetylcysteine also has anti-influenza virus activities. In addition, Acetylcysteine is the most stable form of cysteine during drug delivery and can be used in disulfidptosis studies .
|
-
-
- HY-P99811
-
|
CR57
|
RABV
|
Infection
|
|
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
|
-
-
- HY-P991059
-
|
|
Influenza Virus
|
Infection
|
|
VIS-410 is an antibody inhibitor targeting the stem region of hemagglutinin (HA). VIS-410 inhibits influenza virus replication by blocking HA-mediated membrane fusion. VIS-410 exhibits broad-spectrum neutralization against influenza A viruses with group 1 and group 2 hemagglutinins, including subtypes such as H1N1, H3N2, H5N1, and H7N9 (H5N1 IC50 = 1.5 μg/mL). VIS-410 is applicable to research related to influenza A virus infection .
|
-
-
- HY-P99620
-
|
CT-P22; CT120
|
Influenza Virus
|
Infection
|
|
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
|
-
-
- HY-P991278
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ABM-125 is a IL-25 neutralizer and immune response modulator. ABM-125 neutralizes human and mouse IL-25 and blocks type 2 immune activation function. ABM-125 regulates virus-induced inflammatory cytokine expression and increases the expression level of antiviral interferons in rhinovirus-infected asthmatic bronchial epithelial cells. For the isotype control of ABM-125, refer to Human IgG1 kappa, Isotype Control (HY-P99001). ABM-125 is applicable to research related to virus-induced acute asthma exacerbations .
|
-
-
- HY-P99103
-
|
LY-3853113; LY-COV1404
|
SARS-CoV
|
Infection
|
|
Bebtelovimab a human IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19 ((the IC50 value for SARS-CoV-2/MT020880.1 virus is 9-22.1 ng/mL)). Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .
|
-
-
- HY-122907
-
|
|
Influenza Virus
|
Infection
|
|
JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs) .
|
-
-
- HY-P99792
-
|
NM57; rhRIG
|
RABV
|
Infection
|
|
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
|
-
-
- HY-B0215R
-
|
N-Acetylcysteine (Standard); N-Acetyl-L-cysteine (Standard); NAC (Standard)
|
Reference Standards
Reactive Oxygen Species (ROS)
Endogenous Metabolite
Apoptosis
Ferroptosis
Influenza Virus
Disulfidptosis
|
Infection
Neurological Disease
Cancer
|
|
Acetylcysteine (Standard) is the analytical standard of Acetylcysteine. This product is intended for research and analytical applications. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor . Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases . Acetylcysteine induces cell apoptosis . Acetylcysteine also has anti-influenza virus activities . In addition, Acetylcysteine is the most stable form of cysteine during drug delivery and can be used in disulfidptosis studies .
|
-
-
- HY-W145481A
-
|
Carob galactomannan
|
Sirtuin
|
Inflammation/Immunology
|
|
D-Galacto-D-mannan (Carob galactomannan) is an orally active Dectin-2 agonist. D-Galacto-D-mannan exerts antioxidant activity against hydroxyl radical generation. D-Galacto-D-mannan activates Dectin-2 to trigger downstream signaling pathways, promote the expression of immunoregulatory molecules, coordinate innate and adaptive immune responses, and inhibit excessive inflammatory responses by upregulating the expression of Sirtuin 1. When used as a vaccine adjuvant, D-Galacto-D-mannan induces cellular and humoral immune responses, promotes IFNγ secretion, increases antibody levels and virus neutralization titers, and elevates the levels of immunoglobulin G and A. D-Galacto-D-mannan can serve as an adjuvant for foot-and-mouth disease vaccines, enhance the vaccine-mediated ability of hosts to defend against viral infection in mice, and reduce local side effects at the inoculation site in pigs. D-Galacto-D-mannan can be used in the research of inflammatory and immune diseases, such as foot-and-mouth disease .
|
-
-
- HY-P990817
-
|
|
Dengue Virus
Flavivirus
|
Infection
|
|
Anti-West Nile/dengue virus E protein Antibody (E60) is mouse-derived IgG2a κ type antibody inhibitor, targeting to West Nile/dengue virus E protein. Anti-West Nile/dengue virus E protein Antibody (E60) can cross-neutralize West Nile virus (WNV) and dengue virus (DENV) envelope (E) protein. Anti-West Nile/dengue virus E protein Antibody (E60) can be used for the researches of WNV and DENV infection .
|
-
-
- HY-P5550
-
|
|
Influenza Virus
|
Infection
|
|
Urumin has antiviral activity against the human influenza A virus. Urumin inhibits the growth of PR8 influenza virus (IC50: 3.8 μM). Urumin targets the conserved stalk of H1 hemagglutini, and is effective at neutralizing drug-resistant H1 influenza viruses. Urumin protects naive mice from lethal influenza infection .
|
-
-
- HY-P991764
-
|
|
Dengue Virus
|
Infection
|
|
Anti-Dengue virus type 4 E protein DIII Antibody (DV4-E88) reacts with the DIII domain on the E protein of dengue virus serotype 4 (DENV-4). Anti-Dengue virus type 4 E protein DIII Antibody (DV4-E88) neutralizes 1036, TVP-376, and TVP-986 genotype II strains of DENV-4. Recommend Isotype Controls: Mouse IgG2c kappa, Isotype Control (HY-P99981) .
|
-
-
- HY-B0215S1
-
|
N-Acetylcysteine-15N; N-Acetyl-L-cysteine-15N; NAC-15N
|
Isotope-Labeled Compounds
Reactive Oxygen Species (ROS)
Endogenous Metabolite
Apoptosis
Ferroptosis
Influenza Virus
Disulfidptosis
|
Infection
Neurological Disease
|
|
Acetylcysteine- 15N (N-Acetylcysteine- 15N) is the 15N-labeled Acetylcysteine. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases. Acetylcysteine induces cell apoptosis. Acetylcysteine also has anti-influenza virus activities. In addition, Acetylcysteine is the most stable form of cysteine during drug delivery and can be used in disulfidptosis studies .
|
-
-
- HY-P4042
-
|
hepatitis B peptide 4980
|
HBV
|
Infection
Inflammation/Immunology
|
|
Hepatitis B Virus Receptor Binding Fragment (hepatitis B peptide 4980) is a synthetic peptide analog which specifically binds to Hep G2 cells. Hepatitis B Virus Receptor Binding Fragment is a promising immunogen expected to elicit protective antibodies based on the concept of the attachment blockade pathway of virus neutralization .
|
-
-
- HY-P4025
-
|
|
HIV
|
Others
|
|
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonal antibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .
|
-
-
- HY-P9804
-
|
MERS-2E6; MERS Antibody-2E6
|
SARS-CoV
|
Infection
|
|
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
|
-
-
- HY-P991215
-
|
|
HPV
|
Infection
|
|
Anti-HPV18 L1 Antibody (H18L1-A) is a humanized antibody targeting the L1 protein of human papillomavirus type 18 (HPV18). Anti-HPV18 L1 Antibody (H18L1-A) blocks the binding of the HPV18 virus to cell surface receptors, neutralizing the virus activity, and thus inhibiting the virus from infecting cells. Anti-HPV18 L1 Antibody (H18L1-A) is promising for research of human papillomavirus-related diseases .
|
-
-
- HY-P10976
-
|
|
SARS-CoV
|
Infection
|
|
Spike Glycoprotein (1147-1162) is a linear and broadly neutralizing peptide in the S2 protein of SARS-CoV-2. Spike Glycoprotein (1147-1162) is conserved across SARS-CoV, BatCoV RaTG13, SARS-CoV-2, and SARS-CoV-2 variants. Spike Glycoprotein (1147-1162)-targeting mAbs can neutralize both SARS-CoV-2 and SARS-CoV by preventing fusion between the virus and cell membrane. Spike Glycoprotein (1147-1162) can be used for universal vaccines against SARS-CoV-2 mutants research .
|
-
-
- HY-169335
-
|
|
HIV
|
Infection
|
|
HIV-1 inhibitor-77 (compound 13) is a HIV-1 inhibitor. HIV-1 inhibitor-77 can neutralize all three tested viruses with the IC50 values of 0.14 μM, 8.28 μM and 2.92 μM for HIV-1CH58TF , HIV-1 JRFL and HIV-1 AD8, respectively .
|
-
-
- HY-P990848
-
|
|
CTLA-4
|
Infection
Inflammation/Immunology
|
|
Anti-CTLA-4/CD152 Antibody (BN13) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human CTLA-4/CD152. Anti-CTLA-4/CD152 Antibody (BN13) can neutralize CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. Anti-CTLA-4/CD152 Antibody (BN13) can be used for the researches of infection and immunology, such as human immunodeficiency virus (HIV) .
|
-
-
- HY-P992081
-
|
|
Orthopoxvirus
|
Infection
|
|
Anti-H3L Antibody (NAL_A185) is a neutralizing antibody targeting the H3L envelope protein of vaccinia virus (CV) belonging to the genus Orthopoxvirus. By binding to the H3L protein of intracellular mature virions, Anti-H3L Antibody (NAL_A185) blocks the binding of the virus to host cells, thereby neutralizing viral infectivity. Anti-H3L Antibody (NAL_A185) not only protects BALB/c mice from intranasal challenge with the lethal vaccinia virus WR strain, reducing weight loss and mortality, but also exhibits complement-dependent neutralizing activity against monkeypox virus. Among these properties, NAL_A185 is an immune target induced by the smallpox vaccine Dryvax; it elicits a robust recall antibody response and induces high-titer neutralizing antibodies in mice. Anti-H3L Antibody (NAL_A185) can be used for studies related to vaccinia virus infection, monkeypox and monkeypox disease .
|
-
-
- HY-P992079
-
|
|
Influenza Virus
|
Infection
|
|
Anti-Flu A (H3N2) HA/Hemagglutinin Antibody (CR8043) is an antibody targeting influenza virus hemagglutinin (HA) that specifically neutralizes group 2 influenza viruses. Anti-Flu A (H3N2) HA/Hemagglutinin Antibody (CR8043) is applicable to research related to influenza virus infection .
|
-
-
- HY-P992083
-
|
|
Influenza Virus
|
Infection
|
|
Anti-Influenza HA Antibody (CR9114) is an antibody against influenza virus hemagglutinin. Anti-Influenza HA Antibody (CR9114) binds to the conserved hemagglutinin (HA) stalk region of influenza A and B viruses, and mediates cross-subtype neutralization. Anti-Influenza HA Antibody (CR9114) is applicable for influenza-related research .
|
-
-
- HY-P991741
-
|
|
CMV
|
Infection
|
|
Anti-HCMV gB Antibody (SM5-1) is an efficient neutralizing human monoclonal antibody that targets the human cytomegalovirus (HCMV) glycoprotein B (gB). Anti-HCMV gB Antibody (SM5-1) neutralizes HCMV by blocking the conformational changes of gB and interfering with its binding to the gH/gL complex. Anti-HCMV gB Antibody (SM5-1) can broadly neutralize different virus strains and inhibit the infection of various cell types (such as fibroblasts, epithelial cells, and dendritic cells). Anti-HCMV gB Antibody (SM5-1) can be used in HCMV vaccine research .
|
-
-
- HY-P992078
-
|
|
Influenza Virus
|
Infection
|
|
Anti-Flu A (H3N2) HA/Hemagglutinin Antibody (C05) is a broad-spectrum neutralizing antibody that targets multiple influenza A HA subtypes. Anti-Flu A (H3N2) HA/Hemagglutinin Antibody (C05) is applicable to research related to influenza A virus infection .
|
-
-
- HY-P992175
-
|
|
RSV
|
Infection
|
|
ADI-14448 is a RSV prefusion fusion glycoprotein inhibitor and HMPV fusion glycoprotein inhibitor, with a Kd of 3.8 × 10 -10 M for RSV preF. ADI-14448 binds to epitope III of RSV preF, thereby blocking viral infection. ADI-14448 neutralizes RSV subtype A and HMPV subtype A1. ADI-14448 can be used in studies related to respiratory syncytial virus infection and metapneumovirus infection .
|
-
-
- HY-P992174
-
|
|
RSV
|
Infection
|
|
ADI-14359 is an antibody that binds to RSV postF, with a KD value of 387 nM, and exhibits non-neutralizing activity. ADI-14359 binds to antigenic site I on RSV postF through interactions of its conserved CDR H3 motif, germline-encoded IGKV1-39 light chain residues and heavy chain residues, where the light chain mediates preferential binding to postF by conflicting with the rearranged preF region. ADI-14359 can be used in studies related to respiratory syncytial virus (RSV) infection .
|
-
-
- HY-P992301
-
|
|
RSV
|
Infection
|
|
Anti-RSV F Antibody (R4.C6) is a monoclonal antibody against RSV F, with a Kd of 0.34 nM for the post-fusion RSV F trimer. Anti-RSV F Antibody (R4.C6) recognizes a unique neutralizing epitope spanning epitopes II and IV on both pre-fusion and post-fusion RSV F. Anti-RSV F Antibody (R4.C6) can be used in studies related to respiratory syncytial virus infection .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-153235
-
|
|
Biochemical Assay Reagents
|
|
COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein. COVID-19 Spike Protein undertakes the functions of virus binding with host cell receptors, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design. COVID-19 Spike Protein mRNA-LNP can be used for RNA delivery, vaccine formulation and design targeting SARS-CoV-2 .
|
-
- HY-W145481A
-
|
Carob galactomannan
|
Biochemical Assay Reagents
|
|
D-Galacto-D-mannan (Carob galactomannan) is an orally active Dectin-2 agonist. D-Galacto-D-mannan exerts antioxidant activity against hydroxyl radical generation. D-Galacto-D-mannan activates Dectin-2 to trigger downstream signaling pathways, promote the expression of immunoregulatory molecules, coordinate innate and adaptive immune responses, and inhibit excessive inflammatory responses by upregulating the expression of Sirtuin 1. When used as a vaccine adjuvant, D-Galacto-D-mannan induces cellular and humoral immune responses, promotes IFNγ secretion, increases antibody levels and virus neutralization titers, and elevates the levels of immunoglobulin G and A. D-Galacto-D-mannan can serve as an adjuvant for foot-and-mouth disease vaccines, enhance the vaccine-mediated ability of hosts to defend against viral infection in mice, and reduce local side effects at the inoculation site in pigs. D-Galacto-D-mannan can be used in the research of inflammatory and immune diseases, such as foot-and-mouth disease .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P5364
-
|
|
Peptides
|
Others
|
|
B8R 20-27 is a biological active peptide. (This is amino acids 20 to 27 fragment of B8R, a vaccinia virus (VV) gene that encodes a secreted protein related to gamma interferon receptor. B8R binding to IFN-g neutralizes its antiviral activity.)
|
-
- HY-P5550
-
|
|
Influenza Virus
|
Infection
|
|
Urumin has antiviral activity against the human influenza A virus. Urumin inhibits the growth of PR8 influenza virus (IC50: 3.8 μM). Urumin targets the conserved stalk of H1 hemagglutini, and is effective at neutralizing drug-resistant H1 influenza viruses. Urumin protects naive mice from lethal influenza infection .
|
-
- HY-P4042
-
|
hepatitis B peptide 4980
|
HBV
|
Infection
Inflammation/Immunology
|
|
Hepatitis B Virus Receptor Binding Fragment (hepatitis B peptide 4980) is a synthetic peptide analog which specifically binds to Hep G2 cells. Hepatitis B Virus Receptor Binding Fragment is a promising immunogen expected to elicit protective antibodies based on the concept of the attachment blockade pathway of virus neutralization .
|
-
- HY-P4025
-
|
|
HIV
|
Others
|
|
ELDKWA is the highly conserved amino acids on the ecto-domain of gp41. ELDKWA acts as the epitope of a neutralizing monoclonal antibody 2F5 (mAb 2F5) directed against human immunodeficiency virus type 1 .
|
-
- HY-P10976
-
|
|
SARS-CoV
|
Infection
|
|
Spike Glycoprotein (1147-1162) is a linear and broadly neutralizing peptide in the S2 protein of SARS-CoV-2. Spike Glycoprotein (1147-1162) is conserved across SARS-CoV, BatCoV RaTG13, SARS-CoV-2, and SARS-CoV-2 variants. Spike Glycoprotein (1147-1162)-targeting mAbs can neutralize both SARS-CoV-2 and SARS-CoV by preventing fusion between the virus and cell membrane. Spike Glycoprotein (1147-1162) can be used for universal vaccines against SARS-CoV-2 mutants research .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P99756
-
|
MEDI8897
|
RSV
|
Infection
|
|
Nirsevimab (MEDI8897) is a recombinant monoclonal antibody against human respiratory syncytial virus (RSV). Nirsevimab has neutralizing activity against RSV A and RSV B viruses, with IC50 values of 5.42 ng/mL and 9.71 ng/mL, respectively. Nirsevimab can be used for research on respiratory infections .
|
-
(5)
-
- HY-P990794
-
|
|
TNF Receptor
Dengue Virus
|
Infection
Inflammation/Immunology
Cancer
|
|
Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) is a rat-derived IgG1 antibody inhibitor, targeting to TNF-alpha/TNFSF2. Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) neutralizes of TNF-alpha. Anti-Mouse TNF-alpha/TNFSF2 Antibody (XT3.11) can be used for the researches of cancer, infection and immunology, such as dengue virus and B16K1 tumor .
|
-
(5)
-
- HY-P99750
-
|
CT-P23
|
Influenza Virus
|
Infection
|
|
Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin (HA) of influenza A virus. Navivumab binds to the HA2 stem fusion domain and the low-variability HA2 region of influenza viruses. Navivumab neutralizes influenza A viruses of subtypes H1, H2, H5, and H9. Navivumab is applicable to research related to influenza and influenza A .
|
-
(5)
-
- HY-P990015
-
|
VIR-3434
|
HBV
|
Infection
|
|
Tobevibart (VIR-3434) is a human IgG1 lambda monoclonal antibody against hepatitis B virus (HBV) surface antigen (HBsAg). Tobevibart shows potent neutralization against HBsAg from all HBV genotypes in vitro and inhibits viral entry of HBV and hepatitis delta virus (HDV). Recommend Isotype Controls: Human IgG1 lambda2, Isotype Control (HY-P990096) .
|
-
(5)
-
- HY-P991446
-
|
|
Influenza Virus
|
Infection
|
|
MEDI-8852 is a human IgG1 monoclonal antibody against influenza A virus hemagglutinin (HA). MEDI-8852 binds to the conserved HA stalk epitope and neutralizes viral infectivity. MEDI-8852 reduces viral titers in mouse lung tissues. MEDI-8852 is applicable to research related to pandemic influenza . Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).
|
-
(5)
-
- HY-P99342
-
|
REGN10987
|
SARS-CoV
|
Infection
|
|
Imdevimab (REGN10987) is a human monoclonal antibody that targets SARS-CoV-2 virus. Imdevimab can be used in combination with Casirivimab (HY-P99341) to reduce viral load and transiently increases anti-receptor-binding domain IgG titers. Imdevimab maintains most of its neutralization activity against viruses with B.1.1.7, B.1.351 and mink cluster 5 spike proteins .
|
-
(5)
-
- HY-P990223
-
|
|
Interleukin Related
|
Infection
Others
Inflammation/Immunology
Cancer
|
|
Anti-Mouse IL-15 Antibody (AIO.3) is a rat-derived IgG2a λ type antibody inhibitor, targeting to mouse IL-15. Anti-Mouse IL-15 Antibody (AIO.3) can neutralize IL-15. Anti-Mouse IL-15 Antibody (AIO.3) can be used for the researches of cancer, infection and inflammation, such as hepatitis virus infection and esophagitis .
|
-
(5)
-
- HY-P99811
-
|
CR57
|
RABV
|
Infection
|
|
Rafivirumab (CR57) is an anti-rabies virus monoclonal antibody for the prophylaxis of rabies. Rafivirumab has neutralizing potency against a broad spectrum of RABV variants. Rafivirumab can be used for research of cocktails .
|
-
(5)
-
- HY-P991059
-
|
|
Influenza Virus
|
Infection
|
|
VIS-410 is an antibody inhibitor targeting the stem region of hemagglutinin (HA). VIS-410 inhibits influenza virus replication by blocking HA-mediated membrane fusion. VIS-410 exhibits broad-spectrum neutralization against influenza A viruses with group 1 and group 2 hemagglutinins, including subtypes such as H1N1, H3N2, H5N1, and H7N9 (H5N1 IC50 = 1.5 μg/mL). VIS-410 is applicable to research related to influenza A virus infection .
|
-
(5)
-
- HY-P99620
-
|
CT-P22; CT120
|
Influenza Virus
|
Infection
|
|
Firivumab (CT-P22; CT120) is a human IgG1 monoclonal influenza A virus hemagglutinin (Anti-IAV HA) antibody. Firivumab is capable of neutralizing H1N1, H5N1, H6N1, H6N2, H8N4, H8N8, H9N2 and H12N7. Firivumab shows protection against H1N1 virus in mice .
|
-
(5)
-
- HY-P991278
-
|
|
Interleukin Related
|
Inflammation/Immunology
|
|
ABM-125 is a IL-25 neutralizer and immune response modulator. ABM-125 neutralizes human and mouse IL-25 and blocks type 2 immune activation function. ABM-125 regulates virus-induced inflammatory cytokine expression and increases the expression level of antiviral interferons in rhinovirus-infected asthmatic bronchial epithelial cells. For the isotype control of ABM-125, refer to Human IgG1 kappa, Isotype Control (HY-P99001). ABM-125 is applicable to research related to virus-induced acute asthma exacerbations .
|
-
(5)
-
- HY-P99103
-
|
LY-3853113; LY-COV1404
|
SARS-CoV
|
Infection
|
|
Bebtelovimab a human IgG1-λ2 antibody targeting to SARS-CoV-2, especially COVID-19 ((the IC50 value for SARS-CoV-2/MT020880.1 virus is 9-22.1 ng/mL)). Bebtelovimab potently neutralizes SARS-CoV-2 variants, and inhibits COVID-19 with mild-to-moderate efficacy .
|
-
(5)
-
- HY-P99792
-
|
NM57; rhRIG
|
RABV
|
Infection
|
|
Ormutivimab (rhRIG) is a recombinant human monoclonal antibody, targeting rabies virus. Ormutivimab neutralizes a variety of rabies virus strains. Ormutivimab exhibits potent potency against rabies post-exposure prophylaxis (PEP) model .
|
-
(5)
-
- HY-P990817
-
|
|
Dengue Virus
Flavivirus
|
Infection
|
|
Anti-West Nile/dengue virus E protein Antibody (E60) is mouse-derived IgG2a κ type antibody inhibitor, targeting to West Nile/dengue virus E protein. Anti-West Nile/dengue virus E protein Antibody (E60) can cross-neutralize West Nile virus (WNV) and dengue virus (DENV) envelope (E) protein. Anti-West Nile/dengue virus E protein Antibody (E60) can be used for the researches of WNV and DENV infection .
|
-
(5)
-
- HY-P991764
-
|
|
Dengue Virus
|
Infection
|
|
Anti-Dengue virus type 4 E protein DIII Antibody (DV4-E88) reacts with the DIII domain on the E protein of dengue virus serotype 4 (DENV-4). Anti-Dengue virus type 4 E protein DIII Antibody (DV4-E88) neutralizes 1036, TVP-376, and TVP-986 genotype II strains of DENV-4. Recommend Isotype Controls: Mouse IgG2c kappa, Isotype Control (HY-P99981) .
|
-
(5)
-
- HY-P9804
-
|
MERS-2E6; MERS Antibody-2E6
|
SARS-CoV
|
Infection
|
|
Anti-MERS-2E6 mAb (MERS-2E6; MERS Antibody-2E6), a human neutralizing antibody IgG1 (CHO expressed) that can compete for the binding of the virus Spike protein to the receptor (CD26), thereby inhibiting virus invasion into host cells.
|
-
(5)
-
- HY-P991215
-
|
|
HPV
|
Infection
|
|
Anti-HPV18 L1 Antibody (H18L1-A) is a humanized antibody targeting the L1 protein of human papillomavirus type 18 (HPV18). Anti-HPV18 L1 Antibody (H18L1-A) blocks the binding of the HPV18 virus to cell surface receptors, neutralizing the virus activity, and thus inhibiting the virus from infecting cells. Anti-HPV18 L1 Antibody (H18L1-A) is promising for research of human papillomavirus-related diseases .
|
-
(5)
-
- HY-P990848
-
|
|
CTLA-4
|
Infection
Inflammation/Immunology
|
|
Anti-CTLA-4/CD152 Antibody (BN13) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human CTLA-4/CD152. Anti-CTLA-4/CD152 Antibody (BN13) can neutralize CTLA-4 (cytotoxic T lymphocyte antigen-4) also known as CD152. Anti-CTLA-4/CD152 Antibody (BN13) can be used for the researches of infection and immunology, such as human immunodeficiency virus (HIV) .
|
-
(5)
-
- HY-P992081
-
|
|
Orthopoxvirus
|
Infection
|
|
Anti-H3L Antibody (NAL_A185) is a neutralizing antibody targeting the H3L envelope protein of vaccinia virus (CV) belonging to the genus Orthopoxvirus. By binding to the H3L protein of intracellular mature virions, Anti-H3L Antibody (NAL_A185) blocks the binding of the virus to host cells, thereby neutralizing viral infectivity. Anti-H3L Antibody (NAL_A185) not only protects BALB/c mice from intranasal challenge with the lethal vaccinia virus WR strain, reducing weight loss and mortality, but also exhibits complement-dependent neutralizing activity against monkeypox virus. Among these properties, NAL_A185 is an immune target induced by the smallpox vaccine Dryvax; it elicits a robust recall antibody response and induces high-titer neutralizing antibodies in mice. Anti-H3L Antibody (NAL_A185) can be used for studies related to vaccinia virus infection, monkeypox and monkeypox disease .
|
-
(5)
-
- HY-P992079
-
|
|
Influenza Virus
|
Infection
|
|
Anti-Flu A (H3N2) HA/Hemagglutinin Antibody (CR8043) is an antibody targeting influenza virus hemagglutinin (HA) that specifically neutralizes group 2 influenza viruses. Anti-Flu A (H3N2) HA/Hemagglutinin Antibody (CR8043) is applicable to research related to influenza virus infection .
|
-
(5)
-
- HY-P992083
-
|
|
Influenza Virus
|
Infection
|
|
Anti-Influenza HA Antibody (CR9114) is an antibody against influenza virus hemagglutinin. Anti-Influenza HA Antibody (CR9114) binds to the conserved hemagglutinin (HA) stalk region of influenza A and B viruses, and mediates cross-subtype neutralization. Anti-Influenza HA Antibody (CR9114) is applicable for influenza-related research .
|
-
(5)
-
- HY-P991741
-
|
|
CMV
|
Infection
|
|
Anti-HCMV gB Antibody (SM5-1) is an efficient neutralizing human monoclonal antibody that targets the human cytomegalovirus (HCMV) glycoprotein B (gB). Anti-HCMV gB Antibody (SM5-1) neutralizes HCMV by blocking the conformational changes of gB and interfering with its binding to the gH/gL complex. Anti-HCMV gB Antibody (SM5-1) can broadly neutralize different virus strains and inhibit the infection of various cell types (such as fibroblasts, epithelial cells, and dendritic cells). Anti-HCMV gB Antibody (SM5-1) can be used in HCMV vaccine research .
|
-
(5)
-
- HY-P992078
-
|
|
Influenza Virus
|
Infection
|
|
Anti-Flu A (H3N2) HA/Hemagglutinin Antibody (C05) is a broad-spectrum neutralizing antibody that targets multiple influenza A HA subtypes. Anti-Flu A (H3N2) HA/Hemagglutinin Antibody (C05) is applicable to research related to influenza A virus infection .
|
-
(5)
-
- HY-P992175
-
|
|
RSV
|
Infection
|
|
ADI-14448 is a RSV prefusion fusion glycoprotein inhibitor and HMPV fusion glycoprotein inhibitor, with a Kd of 3.8 × 10 -10 M for RSV preF. ADI-14448 binds to epitope III of RSV preF, thereby blocking viral infection. ADI-14448 neutralizes RSV subtype A and HMPV subtype A1. ADI-14448 can be used in studies related to respiratory syncytial virus infection and metapneumovirus infection .
|
-
(5)
-
- HY-P992174
-
|
|
RSV
|
Infection
|
|
ADI-14359 is an antibody that binds to RSV postF, with a KD value of 387 nM, and exhibits non-neutralizing activity. ADI-14359 binds to antigenic site I on RSV postF through interactions of its conserved CDR H3 motif, germline-encoded IGKV1-39 light chain residues and heavy chain residues, where the light chain mediates preferential binding to postF by conflicting with the rearranged preF region. ADI-14359 can be used in studies related to respiratory syncytial virus (RSV) infection .
|
-
(5)
-
- HY-P992301
-
|
|
RSV
|
Infection
|
|
Anti-RSV F Antibody (R4.C6) is a monoclonal antibody against RSV F, with a Kd of 0.34 nM for the post-fusion RSV F trimer. Anti-RSV F Antibody (R4.C6) recognizes a unique neutralizing epitope spanning epitopes II and IV on both pre-fusion and post-fusion RSV F. Anti-RSV F Antibody (R4.C6) can be used in studies related to respiratory syncytial virus infection .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0215S
-
|
|
|
Acetylcysteine-d3 is the deuterium labeled Acetylcysteine. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases. Acetylcysteine induces cell apoptosis. Acetylcysteine also has anti-influenza virus activities. In addition, Acetylcysteine is the most stable form of cysteine during drug delivery and can be used in disulfidptosis studies .
|
-
-
- HY-B0215S1
-
|
|
|
Acetylcysteine- 15N (N-Acetylcysteine- 15N) is the 15N-labeled Acetylcysteine. Acetylcysteine (N-Acetylcysteine) is a mucolytic agent which reduces the thickness of the mucus. Acetylcysteine is a ROS inhibitor. Acetylcysteine is a cysteine precursor, prevents hemin-induced ferroptosis by neutralizing toxic lipids generated by arachidonate-dependent activity of 5-lipoxygenases. Acetylcysteine induces cell apoptosis. Acetylcysteine also has anti-influenza virus activities. In addition, Acetylcysteine is the most stable form of cysteine during drug delivery and can be used in disulfidptosis studies .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-153235
-
|
|
|
mRNA
Liposome
Antigens
|
|
COVID-19 Spike Protein mRNA-LNP is a lipid nanoparticle (LNP) containing mRNA encoding COVID-19 Spike Protein. COVID-19 Spike Protein undertakes the functions of virus binding with host cell receptors, thereby mediating the entry of COVID-19 virus into cells. COVID-19 Spike Protein is an important site of action for host neutralizing antibodies and a key target for vaccine design. COVID-19 Spike Protein mRNA-LNP can be used for RNA delivery, vaccine formulation and design targeting SARS-CoV-2 .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
